Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate T-cell epitopes in hepatitis B virus X antigen

Citation
Mk. Chung et al., Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate T-cell epitopes in hepatitis B virus X antigen, J IMMUNOTH, 22(4), 1999, pp. 279-287
Citations number
33
Categorie Soggetti
Immunology
Journal title
JOURNAL OF IMMUNOTHERAPY
ISSN journal
15249557 → ACNP
Volume
22
Issue
4
Year of publication
1999
Pages
279 - 287
Database
ISI
SICI code
1524-9557(199907)22:4<279:IOCTLW>2.0.ZU;2-F
Abstract
Cytotoxic T lymphocytes (CTL) have been suggested to contribute to viral cl earance during hepatitis B virus (HBV) infection. To induce effective CTL a gainst viral infection by peptide vaccination, it is essential to identify the epitope peptides recognized by CTL. Here, 15 peptide sequences that con tain HLA-A2.1-restricted CTL binding consensus motif were identified on hep atitis B virus X (HBx) protein and synthesized for further characterization . In the binding assay, 8 of 15 synthetic peptides enhanced the expression of HLA-A2.1 molecules on the surface of T2 cells, a human transport-associa ted antigen processing-deficient cell line. This result implies that these eight peptides are able to bind to the HLA-A2.1 molecules. These peptides w ere further tested for their ability to activate CTL. from peripheral blood mononuclear cells (PBMCs) isolated from HBV chronic carriers. Five of eigh t tested peptides activated PBMC-derived T cells, resulting in the lysis of the target T2 cells pulsed with the same peptide. Furthermore, the CTL res ponses to HBx antigen in HBV chronic carriers were shown to be polyclonal, multispecific, and mediated mainly by CD8(+) T cells. In contrast, these re sponses were not detected in uninfected healthy blood donors. Although the five CTL epitope peptides identified in this study have not been proven to be the naturally processed epitopes in HBV-infected hepatocytes, they could be: candidates for peptide-based immunotherapy against HBV infection.